

Rabbit Anti-ERCC1 [EP219]: RM0093, RM0093RTU7

Intended Use: For Research Use Only

Description: Excision Repair Cross Complementing 1 (ERCC1) is a mammalian nucleotide excision repair (NER) enzyme involved in repair of damaged DNA. ERCC1 is a homologous to RAD10 in *Saccharomyces cerevisiae*, which is required in mitotic intrachromosomal recombination and repair. ERCC1 is required in repair of cisplatin-induced DNA adducts and ultraviolet (UV)-induced DNA damage. High expression of ERCC1 has been linked to tumor progression in a variety of cancers including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head, ovarian cancer and esophageal cancer.


Specifications:

Clone: EP219
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human
 Localization: Nucleus
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC
 Package:

Description	Catalog No.	Size
ERCC1 Concentrated	RM0093	1 ml
ERCC1 Prediluted	RM0093RTU7	7 ml

IHC Procedure*:

Positive Control Tissue: GI tract, lung cancer
 Concentrated Dilution: 10-50
 Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE hepatocellular carcinoma stained with anti-ERCC1 using DAB

References:

1. Expression of excision repair cross-complementation group 1 and class III β -tubulin in thymic carcinoma. Okuda K, et al. *Oncol Lett* 13:3144-3150, 2017.
2. Effects of p38MAPK-mediated excision repair cross-complementation 1 expression on prognosis of patients with non-small cell lung cancer. He D, et al. *Oncol Lett* 14:3463-3472, 2017.
3. High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer. Kim DH, et al. *Oncol Lett* 14:4995-5003, 2017.
4. Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. Millis SZ, et al. *Biomark Cancer* 7:69-76, 2015.

Doc. 100-RM0093
Rev. A